Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

BioCorRx (BICX) Gross Margin (2016 - 2025)

BioCorRx (BICX) has disclosed Gross Margin for 15 consecutive years, with 100.0% as the latest value for Q1 2025.

  • Quarterly Gross Margin rose 4605.0% to 100.0% in Q1 2025 from the year-ago period, while the trailing twelve-month figure was 100.0% through Mar 2025, up 5537.0% year-over-year, with the annual reading at 78.25% for FY2024, 1861.0% up from the prior year.
  • Gross Margin hit 100.0% in Q1 2025 for BioCorRx, roughly flat from 100.0% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 100.0% in Q2 2024 to a low of 31.08% in Q4 2023.
  • Historically, Gross Margin has averaged 79.19% across 5 years, with a median of 88.41% in 2021.
  • Biggest five-year swings in Gross Margin: soared 11244bps in 2021 and later plummeted -5846bps in 2023.
  • Year by year, Gross Margin stood at 82.14% in 2021, then rose by 9bps to 89.53% in 2022, then plummeted by -65bps to 31.08% in 2023, then skyrocketed by 222bps to 100.0% in 2024, then changed by 0bps to 100.0% in 2025.
  • Business Quant data shows Gross Margin for BICX at 100.0% in Q1 2025, 100.0% in Q2 2024, and 53.95% in Q1 2024.